Mucopolysaccharidoses – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of mucopolysaccharidoses (MPS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of MPS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s MPS forecast will answer the following question:
- How will demographic trends, such as changes in birth rates, affect the epidemiology of MPS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts seven MPS patient populations, as follows:
- Diagnosed prevalent cases of MPS.
- Diagnosed prevalent cases of MPS I.
- Diagnosed prevalent cases of MPS II.
- Diagnosed prevalent cases of MPS III.
- Diagnosed prevalent cases of MPS IV.
- Diagnosed prevalent cases of MPS VI.
- Diagnosed prevalent cases of MPS VII.
Note: Coverage may vary by country.
Table of contents
- Mucopolysaccharidoses - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of mucopolysaccharidosis)
- Diagnosed prevalent cases of mucopolysaccharidosis
- Diagnosed prevalent cases of mucopolysaccharidosis I
- Diagnosed prevalent cases of mucopolysaccharidosis I by subtype
- Diagnosed prevalent cases of mucopolysaccharidosis II
- Diagnosed prevalent cases of mucopolysaccharidosis III
- Diagnosed prevalent cases of mucopolysaccharidosis III by subtype
- Diagnosed prevalent cases of mucopolysaccharidosis IV
- Diagnosed prevalent cases of mucopolysaccharidosis IV by subtype
- Diagnosed prevalent cases of mucopolysaccharidosis VI
- Diagnosed prevalent cases of mucopolysaccharidosis VII
- Risk / protective factors applied to disease forecast models
- Reference materials
Madison Kircher, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Kircher completed the CDC/CSTE Applied Epidemiology Fellowship program with the Minnesota Department of Health. She received her M.P.H. from the University of Wisconsin in Madison in 2020.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.